Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2009

View Archived Issues

New mTOR kinase inhibtors reported in recent AstraZeneca patents

New deuterium-enriched eszopiclone analogues reported for insomnia in recent Protia patent

Novel CRF receptor antagonists for depression and other disorders discovered by Taisho researchers

sanofi-aventis researchers report new coagulation factor VIIa inhibitors

NeuroSearch claims novel potassium BK channel modulators for treating Alzheimer's disease

MAPKAP-K2 inhibitors from Wyeth active against rheumatoid arthritis, other inflammatory conditions

Recent AstraZeneca patent imparts new bacterial DNA gyrase inhibitors

New cannabinoid CB2 receptor ligands in development as analgesic agents at Abbott

AstraZeneca launches Seroquel XR for bipolar depression

CytRx initiates phase II/III arimoclomol trial in familial ALS

Endo completes tender offer for shares of Indevus

European Commission approves Efient for acute coronary syndrome

GeoVax starts injections in phase IIa human HIV/AIDS vaccine trial

GTx initiates phase I trial for GTx-758 in advanced prostate cancer

A-804598 and its tritiated radioligand specifically and potently inhibit P2X7 receptors

Phase III Cyzact results fail to meet primary endpoint

Desmoteplase shows no beneficial effects in acute ischemic stroke in phase III clinical trial

JN-403 displays procognitive, antinociceptive, antiepileptic and anxiolytic effects in rodents

Cell Therapeutics sells 50% ownership interest in Zevalin joint venture to Spectrum

Neuralstem puts clinical hold on spinal cord stem cell trial to treat ALS

Actelion acquires thermostable formulation of epoprostenol sodium from GeneraMedix

Schering-Plough and WHO sign agreement for influenza vaccine manufacturing technology

ALK-Abello and Novozymes sign agreement for recombinant allergens

Bavarian Nordic presents positive updated data on phase I/II studies of MVA-BN-HER2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...